Prognostic potential of preoperative diagnostics of radioiodine-resistant well-differentiated thyroid cancer
https://doi.org/10.24884/0042-4625-2025-184-4-18-24
Abstract
The increase in the number of patients with well-differentiated thyroid cancer with frequent detection of its radioiodine refractory forms requires preoperative diagnostics through the development and application of the most effective high-tech examination methods, the most promising of which are molecular genetic studies of puncture material. The results of examination and surgical treatment of 103 patients with well-differentiated thyroid cancer were analyzed, the preoperative examination of which was supplemented by determining the expression of the sodium iodide symporter and the BRAF V600E mutation. The limiting value of nIS was established, which allows predicting the development of cancer resistance to postoperative radioactive iodine therapy, as well as its relationship with the BRAF mutation in order to determine the need to expand the scope of surgical intervention.
About the Authors
P. N. Romashchenko
Military Medical Academy
Russian Federation
Competing Interests:
Russian Federation
Romashchenko Pavel N., Dr. of Sci. (Med.), Professor, Corresponding Member of the RAS, Head of the S. P. Fedorov Department and Clinic of Faculty Surgery
6, Academica Lebedeva str., Saint Petersburg, 194044
Competing Interests:
The authors declare no conflict of interest.
N. A. Maistrenko
Military Medical Academy
Russian Federation
Competing Interests:
Russian Federation
Maistrenko Nicolay А., Dr. of Sci. (Med.), Professor, Academician of the RAS, Professor of the S. P. Fedorov Department and Clinic of Faculty Surgery
6, Academica Lebedeva str., Saint Petersburg, 194044
Competing Interests:
The authors declare no conflict of interest.
M. S. Simonova
Military Medical Academy
Russian Federation
Competing Interests:
Russian Federation
Simonova Maria S., Cand. of Sci. (Med.), Surgeon of the S. P. Fedorov Department and Clinic of Faculty Surgery
6, Academica Lebedeva str., Saint Petersburg, 194044
Competing Interests:
The authors declare no conflict of interest.
D. S. Krivolapov
Military Medical Academy
Russian Federation
Competing Interests:
Russian Federation
Krivolapov Denis S., Cand. of Sci. (Med.), Teacher of the S. P. Fedorov Department and Clinic of Faculty Surgery
6, Academica Lebedeva str., Saint Petersburg, 194044
Competing Interests:
The authors declare no conflict of interest.
References
1. Rumiantsev P.O., Baidak A.G. Interdisciplinary databank in oncoendocrinology: radioiodine refractory differentiated thyroid cancer. Digital Diagnostics. 2022;3(1):86−93. (In Russ.) Doi: 10.17816/DD104745.
2. Pacini F., Fuhrer D.., Elisei R. et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022 Jan 1;11(1):e210046. Doi: 10.1530/ETJ-21-0046.
3. Romashchenko P.N. Sovremenny`e podxody` k diagnostike i xirurgicheskomu lecheniyu xromaffinny`x opuxolej: special`nost` 14.00.27: dissertaciya na soiskanie uchenoj stepeni doktora medicinskix nauk / Romashchenko Pavel Nikolaevich, 2007. – 342 s. (In Russ.)
4. Samohvalova N.A., Maystrenko N.A., Romashchenko P.N. Programmed approach to the treatment of secondary hyperparathyroidism in chronic renal disease. Grekov's Bulletin of Surgery. 2013;172(2):043-046. (In Russ.) Doi: 10.24884/0042-4625-2013-172-2-043-046.
5. Dzhikiya E.L., Avilov O.N., Kiseleva Ya.Yu. et al. Sodium/iodide symporter (NIS): structure, function and role in in thyroid diseases. Vestnik Rossijskogo nauchnogo centra rentgenoradiologii Minzdrava Rossii. 2018;18(1):1-21. (In Russ.)
6. Cazarin J., Dupuy C., Pires de Carvalho D. Redox Homeostasis in Thyroid Cancer: Implications in Na+/I- Symporter (NIS) Regulation. Int J Mol Sci. 2022 May 30;23(11):6129. Doi: 10.3390/ijms23116129.
7. Ravera S., Reyna-Neyra A., Ferrandino G. et al. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017 Feb 10;79:261-289. Doi: 10.1146/annurev-physiol-022516-034125.
8. Tavares C., Coelho M.J., Eloy C. et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr Connect. 2018 Jan;7(1):78-90. Doi: 10.1530/EC-17-0302.
9. Dong H., Shen W.Z., Yan Y.J. et al. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2016 Feb;36(1):77-81. Doi: 10.1007/s11596-016-1545-3.
10. Liu J., Liu Y., Lin Y., Liang J. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. Endocrinol Metab (Seoul). 2019 Sep;34(3):215-225. Doi: 10.3803/EnM.2019.34.3.215.
11. Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. Doi: 10.1089/thy.2015.0020.
12. Paschke R., Cantara S., Crescenzi A. et al. Sobrinho Simoes M. European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. Eur Thyroid J. 2017 Jul;6(3):115-129. Doi: 10.1159/000468519.
13. Scheffel R.S., Dora J.M., Maia A.L. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022 Jan 1;34(1):9-18. Doi: 10.1097/CCO.0000000000000797.
14. Boriskova M.E., Farafonova U.V., Pankova P.A. et al. Surgical tactics optimization for treatment of BRAF positive papillary thyroid cancer. Clinical and experimental thyroidology. 2018;14(1):25-33. (In Russ.) Doi: 10.14341/ket9424
15. Rumyantsev P.O., Borodavina E.V., Kutukova S.I., Vasilyeva E.B. Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice. Head and Neck Tumors (HNT). 2021;11(3):47-55. (In Russ.) Doi: 10.17650/2222-1468-2021-11-3-47-55.
16. Oh J.M., Ahn B.C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics. 2021 Apr 15;11(13):6251-6277. Doi: 10.7150/thno.57689.
17. Sui X., Sui Y., Wang Y. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway. Mol Med Rep. 2018 Jun;17(6):7521-7528. Doi: 10.3892/mmr.2018.8856.
18. Tchekmedyian V., Dunn L., Sherman E. et al. Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid. 2022 Mar;32(3):273-282. Doi: 10.1089/thy.2021.0565.
19. Zhang H., Chen D. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. Thyroid Res. 2018 Oct 11;11:13. Doi: 10.1186/s13044-018-0057-6.
20. Wächter S., Wunderlich A., Greene B.H. et al. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs. Int J Mol Sci. 2018 Jul 17;19(7):2077. Doi: 10.3390/ijms19072077.
21. Lu J., Zhang J., Wang M. et al. A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately? Curr Opin Oncol. 2023 Mar 1;35(2):132-144. Doi: 10.1097/CCO.0000000000000924.
22. Romashchenko P.N., Krivolapov D.S., Simonova M.S. Significance of preoperative determination of the expression of sodium-iodide symporter in the selection of volume surgical intervention and forecast the efficiency of radioiodine therapy in patients with highly differentiated thyroid cancer. Sciences of Europe. 2021;67-2(67):62-67. (In Russ.) Doi: 10.24412/3162-2364-2021-67-2-62-67.
23. Romashchenko P.N., Maistrenko N.A., Krivolapov D.S., Simonova M.S. Molecular-genetic testing in thyroid surgery. Tavricheskij mediko-biologicheskij vestnik. 2021;24(2):118-126. (In Russ.) Doi:10.37279/2070-8092-2021-24-2-118-126.
24. Mudunov A.M., Rumiantsev P.O., Podvyaznikov S.O. et al. Rezolyuciya po itogam E`kspertnogo soveta «Sovremenny`e podxody` k lecheniyu differencirovannogo raka shhitovidnoj zhelezy`, rezistentnogo k terapii radioaktivny`m jodom. Head and Neck Tumors (HNT). 2015; 5 (3): 59-63. (In Russ.)
25. Rumyantsev P.O., Fomin D.K., Rumyantseva U.V. Criteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Head and Neck Tumors (HNT). 2014;(3):4-9. (In Russ.) Doi: 10.17650/2222-1468-2014-0-3-4-9.
26. Romashchenko P.N. Obosnovanie dostupov pri e`ndovideoxirurgicheskix vmeshatel`stvax na nadpochechnikax (kliniko-anatomicheskoe issledovanie): special`nost` 14.01.17: dissertaciya na soiskanie uchenoj stepeni kandidata medicinskix nauk / Romashchenko Pavel Nikolaevich, 2000. – 161 s. (In Russ)
Supplementary files
Review
For citations:
Romashchenko P.N., Maistrenko N.A., Simonova M.S., Krivolapov D.S. Prognostic potential of preoperative diagnostics of radioiodine-resistant well-differentiated thyroid cancer. Grekov's Bulletin of Surgery. 2025;184(4):18-24. (In Russ.) https://doi.org/10.24884/0042-4625-2025-184-4-18-24
Views:
15
Email this article 